Literature DB >> 21350558

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.

L F Peterson1, E Mitrikeska, D Giannola, Y Lui, H Sun, D Bixby, S N Malek, N J Donato, S Wang, M Talpaz.   

Abstract

Philadelphia chromosome positive chronic myeloid leukemia has a progressive course starting in a benign phase and terminating in a blastic phase. In this study, we show that human homolog double minute 2 (HDM2) inhibition, with MI-219-a novel compound, and consequently p53 stabilization induce chronic myeloid leukemia (CML) blast crisis cells to undergo apoptosis regardless of the presence of the T315I mutation in the BCR-ABL kinase domain. The response to MI-219 is associated with the downregulation of c-Myc and the induction of p21(WAF1). The p53 target and pro-apoptotic proteins PUMA, Noxa and Bax are induced, whereas full length Bid protein decreases with increased activity of pro-apoptotic cleaved Bid, and decrease of Mcl-1 is observed by increased caspase activity. CD95/FAS (FAS antigen) receptor is also induced by MI-219, indicating that both intrinsic and extrinsic apoptotic responses are transcriptionally induced. In addition, p53 protein accumulates in the mitochondrial fraction of treated cells involved in transcription-independent induction of apoptosis. We conclude that HDM-2 inhibition with MI-219 effectively induces p53-dependent apoptosis in most blast crisis CML cells, with or without BCR-ABL mutation(s).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350558     DOI: 10.1038/leu.2011.7

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  23 in total

1.  Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Xiaoyan Jiang; Xianliang Hu; Qidong Luo; Jian Li
Journal:  J Biol Chem       Date:  2019-06-24       Impact factor: 5.157

2.  High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Qian Wan; Lijun Fang; Qiong Wu; Jian Li
Journal:  Int J Hematol       Date:  2016-06-06       Impact factor: 2.490

Review 3.  The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Authors:  Naranie Shanmuganathan; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 4.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.

Authors:  Ling Li; Lisheng Wang; Liang Li; Zhiqiang Wang; Yinwei Ho; Tinisha McDonald; Tessa L Holyoake; WenYong Chen; Ravi Bhatia
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

6.  Recruiting TP53 to target chronic myeloid leukemia stem cells.

Authors:  Steven Grant
Journal:  Haematologica       Date:  2020-05       Impact factor: 11.047

Review 7.  Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.

Authors:  Andreas Burchert
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 8.  Targeting p53 by small molecules in hematological malignancies.

Authors:  Manujendra N Saha; Lugui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2013-03-27       Impact factor: 17.388

9.  Evolutionary conservation and network structure characterize genes of phenotypic relevance for mitosis in human.

Authors:  Marek Ostaszewski; Serge Eifes; Antonio del Sol
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

10.  Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen.

Authors:  Lars Herfindal; Lene Myhren; Bjørn Tore Gjertsen; Stein Ove Døskeland; Gro Gausdal
Journal:  BMC Cancer       Date:  2013-07-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.